Dexamethasone-loaded cochlear implants: How to provide a desired "burst release".

Area of Science:

• Biomaterials Science
• Drug Delivery Systems
• Otolaryngology

Background:

• Cochlear implants use iridium platinum electrodes for severe deafness but cause trauma, inflammation, and fibrosis.
• Embedded dexamethasone in implants controls release over years, mitigating trauma and potentially protecting hair cells.
• Current dexamethasone release is low initially, with suboptimal in vivo efficacy, necessitating improved early drug delivery.

Purpose of the Study:

• To enhance the initial burst release of dexamethasone from cochlear implants.
• To improve early drug action and implant functionality by increasing drug dissolution and diffusion.

Main Methods:

• Incorporated dexamethasone sodium phosphate, a water-soluble salt, into silicone matrices of cochlear implants.
• Investigated the effect of varying dexamethasone sodium phosphate concentrations on drug release rates and implant swelling.

Main Results:

• Adding up to 10% dexamethasone sodium phosphate significantly increased early drug release rates.
• Elevated dexamethasone sodium phosphate concentrations led to significant device swelling.

Conclusions:

• Dexamethasone sodium phosphate effectively enhances initial drug release from cochlear implants.
• A critical balance must be achieved between maximizing drug release and minimizing implant swelling for optimal therapeutic outcomes.